350 related articles for article (PubMed ID: 31377200)
1. Biomarkers for epileptogenesis and its treatment.
Engel J; Pitkänen A
Neuropharmacology; 2020 May; 167():107735. PubMed ID: 31377200
[TBL] [Abstract][Full Text] [Related]
2. The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments.
Löscher W
Neuropharmacology; 2020 May; 167():107605. PubMed ID: 30980836
[TBL] [Abstract][Full Text] [Related]
3. Epileptogenesis, traumatic brain injury, and biomarkers.
Engel J
Neurobiol Dis; 2019 Mar; 123():3-7. PubMed ID: 29625256
[TBL] [Abstract][Full Text] [Related]
4. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.
Löscher W; Brandt C
Pharmacol Rev; 2010 Dec; 62(4):668-700. PubMed ID: 21079040
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies.
Łukawski K; Andres-Mach M; Czuczwar M; Łuszczki JJ; Kruszyński K; Czuczwar SJ
Pharmacol Rep; 2018 Apr; 70(2):284-293. PubMed ID: 29477036
[TBL] [Abstract][Full Text] [Related]
6. Past and present definitions of epileptogenesis and its biomarkers.
Pitkänen A; Engel J
Neurotherapeutics; 2014 Apr; 11(2):231-41. PubMed ID: 24492975
[TBL] [Abstract][Full Text] [Related]
7. Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies.
White HS; Löscher W
Neurotherapeutics; 2014 Apr; 11(2):373-84. PubMed ID: 24425186
[TBL] [Abstract][Full Text] [Related]
8. Defining "epileptogenesis" and identifying "antiepileptogenic targets" in animal models of acquired temporal lobe epilepsy is not as simple as it might seem.
Sloviter RS; Bumanglag AV
Neuropharmacology; 2013 Jun; 69():3-15. PubMed ID: 22342985
[TBL] [Abstract][Full Text] [Related]
9. Epilepsy biomarkers.
Engel J; Pitkänen A; Loeb JA; Dudek FE; Bertram EH; Cole AJ; Moshé SL; Wiebe S; Jensen FE; Mody I; Nehlig A; Vezzani A
Epilepsia; 2013 Aug; 54 Suppl 4(0 4):61-9. PubMed ID: 23909854
[TBL] [Abstract][Full Text] [Related]
10. Inflammation and reactive oxygen species as disease modifiers in epilepsy.
Terrone G; Balosso S; Pauletti A; Ravizza T; Vezzani A
Neuropharmacology; 2020 May; 167():107742. PubMed ID: 31421074
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies.
Boison D; Rho JM
Neuropharmacology; 2020 May; 167():107741. PubMed ID: 31419398
[TBL] [Abstract][Full Text] [Related]
12. Selected Molecular Targets for Antiepileptogenesis.
Pawlik MJ; Miziak B; Walczak A; Konarzewska A; Chrościńska-Krawczyk M; Albrecht J; Czuczwar SJ
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575901
[TBL] [Abstract][Full Text] [Related]
13. Analytic Tools for Post-traumatic Epileptogenesis Biomarker Search in Multimodal Dataset of an Animal Model and Human Patients.
Duncan D; Barisano G; Cabeen R; Sepehrband F; Garner R; Braimah A; Vespa P; Pitkänen A; Law M; Toga AW
Front Neuroinform; 2018; 12():86. PubMed ID: 30618695
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
15. Preventing epileptogenesis: A realistic goal?
Terrone G; Pauletti A; Pascente R; Vezzani A
Pharmacol Res; 2016 Aug; 110():96-100. PubMed ID: 27173399
[TBL] [Abstract][Full Text] [Related]
16. Disease modification in epilepsy: from animal models to clinical applications.
Barker-Haliski ML; Friedman D; French JA; White HS
Drugs; 2015 May; 75(7):749-67. PubMed ID: 25925798
[TBL] [Abstract][Full Text] [Related]
17. The path from scientific discovery to cures for epilepsy.
Carvill GL; Dulla CG; Lowenstein DH; Brooks-Kayal AR
Neuropharmacology; 2020 May; 167():107702. PubMed ID: 31301334
[TBL] [Abstract][Full Text] [Related]
18. Drug-mediated neuroprotection and antiepileptogenesis: animal data.
Pitkänen A
Neurology; 2002 Nov; 59(9 Suppl 5):S27-33. PubMed ID: 12428029
[TBL] [Abstract][Full Text] [Related]
19. Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Liu SJ; Zheng P; Wright DK; Dezsi G; Braine E; Nguyen T; Corcoran NM; Johnston LA; Hovens CM; Mayo JN; Hudson M; Shultz SR; Jones NC; O'Brien TJ
Brain; 2016 Jul; 139(Pt 7):1919-38. PubMed ID: 27289302
[TBL] [Abstract][Full Text] [Related]
20. Models in research of pharmacoresistant epilepsy: present and future in development of antiepileptic drugs.
Kovács R; Heinemann U
Curr Med Chem; 2014; 21(6):689-703. PubMed ID: 24251565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
